For borderline cases of MDS and AML, with blast counts nearing the 20% cutoff, NGS can further support the AML diagnosis if certain molecular findings, such as mutations in the NPM1, FLT3 and CEBPA genes, are detected. The gene discussed is NPM1; the disease is acute myeloid leukemia.